Join to access to all OVN content. Join for Free
Humanizing Cancer Treatment Through Whole-Person Care
City of Hope Academic Research palliative care quality of life pain management

Humanizing Cancer Treatment Through Whole-Person Care


Share This Article



Summary

Dr. Betty Ferrell on her global legacy in palliative care and why whole-person treatment is as crucial as fighting cancer itself.

In this episode of On the Edge of Breakthrough: Voices of Cancer Research, Dr. Monty Pal sits down with Dr. Betty Ferrell, trailblazing nurse-scientist and director of the Division of Nursing Research and Education at City of Hope. Known globally for her foundational work in quality of life, pain management, and palliative care, Dr. Ferrell reflects on her nearly four decades of research, mentorship, and advocacy that have reshaped how we define patient-centered cancer care.

Together they trace her journey from bedside nursing in Oklahoma to spearheading research that has influenced standards of care across disciplines—from bone marrow transplantation and thoracic surgery, to early-phase clinical trials. Dr. Ferrell shares her international collaborations, including her work in Ethiopia with colleague Dr. Lesley Taylor, which are driving change in some of the most resource-constrained settings.

This episode is a reminder that treating cancer isn’t just about targeting disease—it’s about recognizing the full human experience behind it.

Click for Source

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020
OVN Avatar Yichen Zhang, MSc; Huseyin Naci, PhD; Anita K. Wagner, PharmD, DrPH

Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020

Article
Towards a novel approach guiding the decision-making process for anticancer treatment in patients with advanced cancer: framework for systemic anticancer treatment with palliative intent
OVN Avatar K. Ribi, N. Kalbermatten, M. Eicher, F. Strasser

Towards a novel approach guiding the decision-making process for anticancer treatment in patients with advanced cancer: framework for systemic anticancer treatment with palliative intent

Article
Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1
OVN Avatar Daan Geert Knapen, Nathan I. Cherny, Panagiota Zygoura, Nicola Jane Latino, Jean-Yves Douillard, Urania Dafni, Elisabeth G.E. de Vries, Derk Jan de Groot

Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1

Article
Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015
OVN Avatar Nicole Grossmann, Martin Robausch, Eleen Rothschedl, Claudia Wild, Judit Simon

Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015

Article
Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
OVN Avatar Ariadna Tibau, Consolación Molto, Alberto Ocana, Arnoud J Templeton, Luis P Del Carpio, Joseph C Del Paggio, Agustí Barnadas, Christopher M Booth, Eitan Amir

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration

Explore OVN